IRWD vs. ZNTL, CYRX, IGMS, KURA, BHC, FOLD, NVAX, GERN, CLDX, and MYGN
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Zentalis Pharmaceuticals (ZNTL), Cryoport (CYRX), IGM Biosciences (IGMS), Kura Oncology (KURA), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Novavax (NVAX), Geron (GERN), Celldex Therapeutics (CLDX), and Myriad Genetics (MYGN).
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations, community ranking and institutional ownership.
Ironwood Pharmaceuticals currently has a consensus price target of $18.40, suggesting a potential upside of 181.35%. Zentalis Pharmaceuticals has a consensus price target of $31.67, suggesting a potential upside of 203.03%. Given Zentalis Pharmaceuticals' higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.
Zentalis Pharmaceuticals has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ironwood Pharmaceuticals received 452 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. However, 65.00% of users gave Zentalis Pharmaceuticals an outperform vote while only 61.09% of users gave Ironwood Pharmaceuticals an outperform vote.
In the previous week, Ironwood Pharmaceuticals had 4 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 9 mentions for Ironwood Pharmaceuticals and 5 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.80 beat Ironwood Pharmaceuticals' score of 0.70 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Ironwood Pharmaceuticals' net margin of -254.41%. Ironwood Pharmaceuticals' return on equity of -28.45% beat Zentalis Pharmaceuticals' return on equity.
Ironwood Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.
Summary
Ironwood Pharmaceuticals beats Zentalis Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
